Contribute Try STAT+ Today

Amid concerns over a lack of transparency Covid-19 product development, more than two dozen academics and health policy experts are urging federal officials and several vaccine makers to fully disclose all information concerning their clinical trial protocols and agreements.

In an open letter, they acknowledged that sharing such details is unusual, but in this instance, such a step would help to ensure accountability, advance scientific understanding, and build public trust, especially at a time when the race to develop a safe and effective Covid-19 vaccine has become highly politicized by the Trump administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.